Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.5K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

109
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
109
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.7K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.7K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

11.4K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.4K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

258
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
258
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.2K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autoantibodies in hospitalised patients with COVID-19.

Clinical & translational immunology·2024
Same author

Comprehensive Enteroviral Serology Links Infection and Anti-Melanoma Differentiation-Associated Protein 5 Dermatomyositis.

ACR open rheumatology·2024
Same author

Precise identification and tracking of HMGCR-reactive CD4+ T cells in the target tissue of patients with anti-HMGCR immune-mediated necrotising myopathy.

Annals of the rheumatic diseases·2024
Same author

The Relationship Between Anti-Cell Division Cycle and Apoptosis Regulator 1 Autoantibodies, Anti-Sp4 Autoantibodies, and Cancer in Anti-Transcription Intermediary Factor 1γ-Positive Dermatomyositis.

ACR open rheumatology·2024
Same author

Evaluating CA-125 and PET/CT for cancer detection in idiopathic inflammatory myopathies.

Rheumatology (Oxford, England)·2024
Same author

The Interaction of Borrelia burgdorferi with Human Dendritic Cells: Functional Implications.

Journal of immunology (Baltimore, Md. : 1950)·2023

Related Experiment Video

Updated: Dec 17, 2025

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
10:55

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

553

Statin-Associated Autoimmune Myopathy: Current Perspectives.

Eleni Tiniakou1

  • 1Johns Hopkins University School of Medicine, Department of Medicine, Division of Rheumatology, Baltimore, MD, USA.

Therapeutics and Clinical Risk Management
|June 26, 2020
PubMed
Summary

Statins can cause muscle damage, including a rare immune-mediated necrotizing myopathy (IMNM) linked to antibodies against HMGCR. This condition requires immunosuppressive therapy for effective treatment.

Keywords:
anti-HMGCRmyopathystainsstatin myopathystatin toxicity

More Related Videos

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.7K

Related Experiment Videos

Last Updated: Dec 17, 2025

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
10:55

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

553
Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.7K

Area of Science:

  • Immunology
  • Neurology
  • Pharmacology

Background:

  • Statins are widely used cholesterol-lowering drugs.
  • Muscle-related side effects are common in statin users.
  • Statin-associated immune-mediated necrotizing myopathy (IMNM) is a rare but severe adverse effect.

Purpose of the Study:

  • To review the clinical aspects of anti-HMGCR IMNM.
  • To discuss diagnostic methods and genetic risk factors.
  • To explore therapeutic options and pathogenesis of statin-induced IMNM.

Main Methods:

  • Literature review of clinical studies and case reports.
  • Analysis of diagnostic criteria and biomarkers.
  • Examination of genetic associations and treatment outcomes.

Main Results:

  • Anti-HMGCR IMNM presents as a necrotizing myopathy.
  • Diagnosis involves autoantibody testing against HMGCR.
  • Genetic factors may influence susceptibility.
  • Immunosuppressive therapy is the mainstay of treatment.

Conclusions:

  • Anti-HMGCR IMNM is a distinct autoimmune myopathy triggered by statins.
  • Early diagnosis and appropriate immunosuppression are crucial for patient outcomes.
  • Further research into pathogenesis and targeted therapies is warranted.